Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
abbvie, adulterated, aerosol, agonist, air, Alexza, alfa, Alkem, Allergan, alprazolam, annum, Apokyn, apomorphine, artificially, assembled, assembly, Aurobindo, avoid, Batycky, bioavailability, biomarker, bloodstream, breakdown, built, Burwell, cancelled, carbidopa, certified, Chelsea, cimaglermin, clearance, closure, Coalition, collateral, Colorado, column, Computershare, contrast, conventional, Corregidor, counterfeit, CRL, CVT, cyber, decarboxylase, deep, Deferral, denial, Depomed, desirable, desired, discharge, dopa, dopamine, doubt, dry, drying, dumping, Duopa, earliest, emission, episode, escalation, escrow, feature, filer, finite, FL, footnote, fundamental, gastric, gastrointestinal, GlaxoSmithKline, GMP, goodwill, greatest, hae, Head, hedge, Hindman, housed, hybrid, Hyouk, IDE, illegitimate, Impax, implanted, indenture, Inhalation, inhaled, inhaler, inhibitor, intentionally, inter, interlocutory, intestinal, intestine, intrusion, invasion, invasive, IPR, IRB, landlord, leadership, Lee, levodopa, lieu, MA, main, malware, MannKind, migraine, mimic, mobility, molding, Morgan, NeuroDerm, newest, Northern, occupied, oppose, overlease, par, Parkinson, PD, permission, pioneer, PMA, poll, postmarket, powder, pramipexole, premarket, promptly, pronouncement, provisional, PSWD, Pulmatrix, pulmonary, QD, QP, quarantine, quarantined, rank, raw, rebuilt, recommission, reconsider, redeem, redeemed, redemption, refinance, remediation, remedy, representation, reprioritization, reprioritized, restitution, restructuring, retired, revalidate, Rick, room, rotigotine, Roxane, RYTARY, satisfactorily, semiannually, sensitivity, Shareholder, Sinemet, sophisticated, sound, spin, SRS, stolen, strictly, sublease, subleased, sublingual, subordinated, Subtopic, surgically, surrendered, suspect, suspected, temperature, tongue, tremor, triptan, Trust, trustee, tube, undergone, underwriter, underwriting, underwritten, unfit, unreliable, unsecured, unsettled, USA, Valeant, Vectura, Vice, vulnerable, warranty, water, week, Wilmington, workforce
Removed:
accidental, acetonitrile, Aetna, afforded, altered, Amerisource, AMT, aspect, Australia, Biovest, bottle, buprenophine, chloride, chloroform, CP, dehydrated, depletion, distinct, empty, enabled, environment, ether, ethyl, exploitation, faith, formaldehyde, functional, Glial, glycol, hazard, implementation, improperly, irrevocable, isopropanol, ketamine, lesion, MAA, magnesium, Master, matter, methanol, monoclonal, musculoskeletal, pentobarbital, polyethylene, polymer, prevail, promoted, recalled, reclassified, recordkeeping, reformulation, rejected, remit, replacing, restoring, resume, rigorously, ruling, Separation, sodium, sponsorship, stabilized, sufficiently, TBI, tolerable, umbrella, unavailability, undiscounted, vest, vested, Wessel, xylene, Zealand
Filing tables
Filing exhibits
- 10-K Annual report
- 10.31 Stock Option Certificate
- 10.32 Restricted Stock Agreement
- 10.36 Lease Agreement
- 10.37 First Lease Amendment
- 10.38 Second Lease Amendment
- 10.39 Sublease
- 10.75 Asset Purchase Agreement
- 10.76 First Apa Amendment
- 10.77 Second Apa Amendment
- 21 List of Subsidiaries
- 23 E&y Consent
- 31.1 CEO Certification
- 31.2 CFO Certification
- 32.1 CEO Certification
- 32.2 CFO Certification
- Download Excel data file
- View Excel data file
Related press release
ACORQ similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report on Form 10-K of Acorda Therapeutics, Inc. (the “Company”) for the fiscal year ended December 31, 2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Ron Cohen, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
/s/ RON COHEN
Chief Executive Officer
(Principal Executive Officer)
February 27, 2015
[A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Acorda Therapeutics, Inc. and will be retained by Acorda Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.]